QUEBEC CITY, Jan. 7, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR)
announced today that the Corporation will release its fourth quarter
and fiscal year 2012 operating results on January 11, 2013, at 4:00
p.m. (EST). DiagnoCure's management will host a conference call the
same day, at 4:30 p.m. (EST). Interested participants may listen to the
call by dialing 1-888-231-8191 or 514-807-9895 and referencing code
86003400 approximately 15 minutes prior to the call. The Corporation
will also provide a live webcast of the call. Interested participants
may access the webcast on DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations. A replay of the
webcast will be available on DiagnoCure's website for those unable to
participate in the live webcast.
DiagnoCure (TSX: CUR) is a life sciences corporation that develops and
commercializes high-value cancer diagnostic tests that increase
clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and
granted the worldwide exclusive rights to this test to Signal Genetics
in June 2011. The Corporation has also granted a worldwide exclusive
license agreement to Gen-Probe, now a wholly-owned subsidiary of
Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the
development and commercialization of a prostate cancer test using PCA3,
DiagnoCure's proprietary molecular biomarker. Gen-Probe's PROGENSA®
PCA3 test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and the United States. For more
information, visit www.diagnocure.com.
This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forward-looking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forward-looking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DIAGNOCURE INC.